U.S. Senate finance committee asks for Mylan EpiPen rebate investigation


The U.S. Senate Finance Committee on Tuesday said it had asked the U.S. Department of Health and Human Services to investigate the rebates to state Medicaid programs for Mylan Inc's EpiPen treatment.

Mylan, which has raised the U.S. price for a pack of two EpiPens from less than $100 when it acquired the product in 2007 to more than $600, also faces scrutiny from New York Attorney General Eric Schneiderman and West Virginia.

Continue Reading Below

(Reporting by Caroline Humer; Editing by Bill Rigby)